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Abstract P19 embryonal carcinoma cells are known to
differentiate into neurons and glia when treated with relatively
high concentrations (s 100 nM) of retinoic acid (RA).
Concomitant with this RA-induced neural differentiation, we
observed an activation of the c-Jun amino-terminal kinase
(JNK). JNK was required for the RA-induced neural differentia-
tion, because dominant-negative JNK blocked the differentia-
tion. Studies using protein phosphatase inhibitors and protein
kinase inhibitors suggested that both okadaic acid-sensitive
protein phosphatase(s) and protein kinase C participate in the
RA-induced activation of JNK. ß 2001 Published by Elsevier
Science B.V. on behalf of the Federation of European Biochem-
ical Societies.
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1. Introduction
P19 cells are a murine embryonal carcinoma cell line that
have been used extensively as a model system for studying
early embryonic development and di¡erentiation. These plu-
ripotent cells resemble the inner cell mass of early embryos
and can di¡erentiate into endoderm, mesoderm or ectoderm
depending on the culture conditions [1^3]. Treatment of ag-
gregated P19 cells with low concentrations (10 nM) of retinoic
acid (RA) leads to di¡erentiation to endodermal and meso-
dermal derivatives [1^3]. At higher concentrations (s 100
nM) of RA, P19 cells can be stimulated to form neurons
and glia [1^3].
Studies on signaling systems responsible for the RA-in-
duced di¡erentiation of P19 cells have indicated that the
c-Jun amino-terminal kinase (JNK) signaling pathway plays
important roles [4,5]. Expression of a dominant-negative form
of JNK (dnJNK) blocked RA-induced endodermal di¡eren-
tiation [4]. In addition, stable expression of c-Jun in P19 cells
have been found to induce endodermal and mesodermal dif-
ferentiation [5]. These observations indicate that the activity
of JNK is required for either endodermal or mesodermal dif-
ferentiation of P19 cells. However, it is not known whether
JNK is a major player in the neural di¡erentiation of P19
cells, which is induced by high concentrations of RA.
Here, we present evidence that the activation of JNK
through a pathway which is sensitive to both protein phos-
phatase 1 and 2A inhibitors and protein kinase C (PKC) in-
hibitors is required for the RA-induced neural di¡erentiation
of P19 cells.
2. Materials and methods
2.1. Materials
The restriction enzymes and other modifying enzymes for DNA
manipulation were purchased from Takara (Kyoto, Japan).
[Q-32P]ATP (3000 Ci/mmol) was from DuPont-New England Nuclear
(Boston, MA, USA). The anti-mouse neuro¢lament-L (NF-L) and
anti-Flag antibodies were from Zymed Labs (San Francisco, CA,
USA). The anti-SAPK/JNK antibodies were from Santa Cruz (Santa
Cruz, CA, USA). The anti-phospho-SAPK/JNK antibody and the
SAPK/JNK assay kit were purchased from New England Biolabs
(Beverly, MA, USA). Anti-mouse and anti-rabbit IgG-alkaline phos-
phatase conjugates were from Promega (Madison, WI, USA). PKC
inhibitors (calphostin C and chelerythrine chloride) were from Biomol
(Plymouth Meeting, USA). All other reagents used were from Wako
Pure Chemical (Osaka, Japan).
2.2. Methods
2.2.1. Preparation of expression plasmids. A dominant-negative
point mutant of JNK1 was prepared by substitution of phosphoryla-
tion sites (Thr183 and Tyr185) of wild-type (wt)JNK1 (a gift from Dr.
Michael Karin, University of California in San Diego, CA, USA) with
Ala and Phe, respectively, using a site-directed mutagenesis kit (Ta-
kara). The resulting mutant DNA was designated by JNK1(APF). A
Flag-tag was inserted into the amino-terminal end of JNK1 and
JNK1(APF) using polymerase chain reaction (PCR). Both wtJNK
and mutant JNK1 were subcloned into the pCX expression vector
(provided by Dr. Taeko Miyagi, Miyagi Cancer Centre, Japan) and
named pCX-Flag-JNK1 and pCK-Flag-JNK1(APF), respectively.
2.2.2. Cell culture and transfection. P19 EC cells were obtained
from the American Tissue Culture Center (Rockville, USA) and cul-
tured in bicarbonate-bu¡ered K-modi¢ed Eagle’s medium supple-
mented with 10% (v/v) fetal calf serum under a humidi¢ed atmosphere
with 5% (v/v) CO2 in air at 37‡C. To induce neural di¡erentiation, the
cells were cultured on bacterial-grade dishes to form aggregates (ag-
gregation culture) for 4 days in the presence of 1 WM all-trans RA,
then replated on tissue culture-grade dishes and cultured (monolayer
culture) for 3 more days without RA [6]. For the treatment with
inhibitors, the cells were preincubated with okadaic acid (OA, 10
nM), tautomycin (50 nM), calphostin C (0.25 WM) or chelerythrine
chloride (3 WM) for 30 min at 37‡C before RA was added to the
medium. These protein phosphatase inhibitors and PKC inhibitors
were present in the culture medium throughout the 7-day di¡erentia-
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tion process. For stable transfection, P19 cells were co-transfected
with pBABE, encoding the puromycin resistant gene, and pCX-
Flag-JNK1 or pCX-Flag-JNK1(APF) using the Lipofectamine meth-
od (Gibco BRL, Rockville, USA). Puromycin-resistant colonies were
isolated after selection.
2.2.3. Preparation of cell extracts and immunoblot analysis. The
cells were washed twice with ice-cold phosphate-bu¡ered saline
(PBS) and suspended in a lysis bu¡er (20 mM Tris^HCl, pH 7.4,
150 mM NaCl, 1 mM EGTA, 1% (v/v) Triton X-100, 50 mM NaF,
1 mM L-glycerophosphate, 2.5 mM sodium pyrophosphate, 1 mM
Na3VO4, 1 Wg/ml leupeptin and 1 mM phenylmethylsulfonyl £uoride).
Each suspension was centrifuged at 10 000Ug for 10 min and the
resulting supernatant was used as cell extracts. Aliquots of the ex-
tracts (20 Wg protein) were subjected to SDS^polyacrylamide gel elec-
trophoresis (SDS^PAGE), then electrotransferred onto PVDF trans-
fer membranes (Amersham Pharmacia Biotech, Buckinghamshire,
UK), and immunostained with the indicated antibodies. The immu-
noreactivity was detected with chemiluminescent CDS-StarTM
(Boehringer Mannheim, Mannheim, Germany). Protein concentra-
tions were determined using the Bio-Rad protein assay kit (Bio-Rad
Laboratories, Hercules, CA, USA).
2.2.4. Protein kinase assay. Determination of JNK activity in the
cell extracts was performed by immune complex kinase assay using
GST-fused c-Jun as the substrate for JNK, as described previously [7].
Aliquots of the cell extracts (500 Wg proteins) were immunoprecipi-
tated with anti-JNK and protein A-agarose beads. The immunopre-
cipitates were resuspended in 30 Wl of kinase reaction bu¡er A (25 mM
Tris^HCl, pH 7.4, 5 mM L-glycerophosphate, 0.1 mM Na3VO4, 2 mM
DTT and 20 mM MgCl2) containing 3 Wg of GST-c-Jun, 50 WM ATP
and 5 WCi [Q-32P]ATP, and incubated for 15 min at 30‡C. The reac-
tions were terminated by addition of the SDS sample bu¡er, resolved
on SDS^PAGE and the incorporation of 32P into the substrate pro-
teins was visualized and quantitated with the BAS 2000 imaging ana-
lyzer (Fuji, Tokyo, Japan).
2.2.5. Detection of apoptosis and immunostaining of cells. The cells
on day 5.5 of the neural di¡erentiation process were ¢xed in 4% (w/v)
Fig. 1. Activities of JNK in the course of RA-induced neural di¡erentiation of P19 cells. A: Photomicrographs showing RA-induced neurite
outgrowth of P19 cells are depicted. P19 cells (day 0, a) were cultured in the absence (b) or in the presence (c) of 1 WM RA on bacterial grade
culture dishes for 4 days, then replated onto the tissue culture grade dishes and cultured for another 3 days in the absence of RA. B: P19 cells
were treated as described in the legend of A and harvested at day 0, 4 and 7. Aliquots of cell extracts (500 Wg proteins) were immunoprecipi-
tated with anti-JNK antibody and the kinase activity was determined by the incorporation of 32P into GST-c-Jun (upper panel). The protein
level of JNK was monitored by immunoblot analysis using anti-JNK antibody (lower panel). The results represent one of three independent ex-
periments. C: The cells on day 5.5 of the neural di¡erentiation process were stained with an in situ apoptosis detection kit (a). The fragmented
DNA of a TUNNEL-positive cell is shown. The cells were also stained with anti-phospho-JNK antibody (b) or Hoechst 33258 (c).
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paraformaldehyde in PBS for 15 min. The ¢xed cells were then per-
meabilized with 0.1% (v/v) Triton X-100. Apoptotic cells were stained
with an in situ apoptosis detection kit (Takara) according to the
manufacturer’s instructions. Subsequently, the cells were incubated
with anti-phospho-JNK antibody (New England Biolabs) for 1 h,
then immunodetected with Cy3-conjugated goat anti-rabbit IgG
(Jackson Immunoresearch, PA, USA).
3. Results
3.1. JNK is activated in the course of RA-induced neural
di¡erentiation of P19 cells
The morphological changes during the course of RA-depen-
dent neural di¡erentiation of P19 EC cells are shown in Fig.
Fig. 2. E¡ect of expression of wtJNK or dominant-negative JNK on the RA-induced neural di¡erentiation of P19 cells. P19 cells were co-trans-
fected with pBABE, encoding puromycin-resistant gene, and the expression plasmid of pCX-Flag-JNK1 or pCX-Flag-JNK1(APF) using the
Lipofectamine method. Puromycin-resistant colonies of cells were isolated and the expression levels of the endogenous and ectopic forms of
JNK were examined by immunoblot analysis using anti-JNK antibody (A). The extracts of P19 cells transiently transfected with pCX-Flag-
JNK1 plasmid was used as the positive control (con). The transfectants of the wild-type (B) and the mutant forms (C) of JNK were treated
with RA as described in the legend of Fig. 1 and harvested at day 0 or day 7. The JNK activities of the transfectants were determined by
phosphorylation of GST-c-Jun using a speci¢c anti-phospho-c-Jun antibody (SAPK/JNK assay kit) (B and C, upper panels). The expression of
NF-L was examined by immunoblotting with the anti-NF-L antibody (B and C, lower panels). The results shown in B and C represent one of
three independent experiments. The microscopic appearance of the cells transfected with pCX-Flag-JNK1 (D, left panel) or pCX-Flag-
JNK1(APF) (D, right panel) on day 7 is shown.
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1A. While these cells retained a ¢broblast-like appearance for
7 days in culture without added RA (Fig. 1A-b), neurite out-
growth was observed on day 7 of the RA-induced neural
di¡erentiation process (Fig. 1A-c). No change in JNK activity
was observed in the cell extracts on day 4 of the 7-day di¡er-
entiation process, whether or not RA had been added (Fig.
1B, upper panel). By day 7 without RA there was a slight
increase in JNK kinase activity. In contrast, RA treatment
produced a large increase in JNK kinase activity starting at
day 5, measured by 32P incorporation into GST-c-Jun. In the
experiment shown, there was a 7.7-fold increase in JNK ac-
tivity at day 7, compared to day 7 control without added RA
(1.9 vs. 14.6) (Fig. 1B, upper panel). In parallel with the in-
creased activity, the phosphorylation of JNK detecting by
anti-phospho-SAPK/JNK (Thr183/Tyr185) antibody, was en-
hanced on day 7 of the RA-induced di¡erentiation process
Fig. 3. E¡ects of protein phosphatase inhibitors and PKC inhibitors on the phosphorylation of JNK and RA-induced neural di¡erentiation of
P19 cells. A, B: P19 cells were treated with or without 10 nM OA or 50 nM tautomycin (A) or 0.25 WM calphostin C or 3 WM chelerythrine
chloride (B) throughout the 7-day di¡erentiation process. Untreated cells were used as a control. On the 7th day, the cells were harvested and
lysed. The phosphorylation levels of JNK were examined by immunoblot analysis using anti-phospho-JNK antibody (top panels). The protein
levels of JNK were monitored by immunoblot analysis using anti-JNK antibody (middle panels). The expression of NF-L was determined by
immunoblot analysis using anti-NF-L antibody (bottom panels). C: The microscopic appearance of the cells on day 7 in the presence of cal-
phostin C (left panel) or chelerythrine chloride (right panel) is shown.
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(Fig. 3A,B), with little change in the JNK protein levels over
the course of di¡erentiation (Fig. 1B, lower panel). Immuno-
staining of the cells at day 5.5 of the di¡erentiation process
with anti-phospho-JNK antibody indicated that active JNK is
localized in the nuclei of TUNNEL-negative cells (Fig. 1C).
These results indicate that selective activation of JNK by
phosphorylation takes place in the course of RA-induced neu-
ral di¡erentiation of P19 cells.
3.2. dnJNK suppresses the RA-induced neural di¡erentiation of
P19 cells
We established P19 cell lines stably expressing wtJNK and
P19 cell lines stably expressing dnJNK (T183A/Y185F) (Fig.
2A). As shown in Fig. 2B (upper panel), in non-transfected
P19 cells RA-induced neural di¡erentiation corresponded to a
3.3-fold increase in JNK activity measured by anti-phospho-c-
Jun immunoblotting. By comparison, P19 cells stably express-
ing wtJNK showed a 4.8-fold increase in JNK activity after
7 days of RA-induced neural di¡erentiation. No change in
JNK activity or ¢broblast phenotype was observed in the
cell line expressing the wtJNK without added RA (data not
shown). Concomitant with the enhanced activity of JNK, the
expression level of NF-L (Fig. 2B, lower panel) and the neu-
rite outgrowth (Fig. 2D, left panel) were also enhanced by the
ectopic expression of wtJNK. In contrast, the cell line express-
ing the dnJNK (dn1, dn2) did not show increased JNK activ-
ity relative to the control cells at day 7 of the RA-induced
di¡erentiation process (Fig. 2C, upper panel). In addition,
both NF-L expression (Fig. 2C, lower panel) and the neurite
outgrowth (Fig. 2D, right panel) were substantially sup-
pressed in the cells expressing the dnJNK, compared to the
control cells. These results indicate that activation of JNK is
required for the RA-induced neural di¡erentiation of P19
cells. This, plus other evidence, also suggest that the activation
of JNK is commonly required for the di¡erentiation of P19
cells into derivatives of all three germ layers ^ endoderm,
mesoderm and ectoderm.
3.3. Treatment with protein phosphatase inhibitors or PKC
inhibitors suppresses phosphorylation of JNK in the course
of RA-induced neural di¡erentiation of P19 cells
We have already reported that RA-induced di¡erentiation
of P19 cells was inhibited by the presence of the protein phos-
phatase inhibitors OA or tautomycin in the culture medium
throughout the di¡erentiation process [6]. Therefore, we
studied whether the treatment with OA or tautomycin would
a¡ect the phosphorylation of JNK during the course of di¡er-
entiation. As shown in Fig. 3A (top panel), the di¡erentiation-
dependent increase in the phosphorylation of JNK was sub-
stantially suppressed by the presence of OA or tautomycin in
the culture medium. In parallel with the suppression of JNK
phosphorylation, the di¡erentiation-dependent increase in the
expression of NF-L was also inhibited by OA or tautomycin,
as previously observed (Fig. 3A, bottom panel) [6].
It has been reported that overexpression of epsilon-PKC
markedly increased nerve growth factor (NGF)-induced neu-
rite outgrowth of PC12 cells [8]. PKC also participates in the
activation of JNK [9^13]. Addition of two membrane-perme-
able inhibitors of PKC, calphostin C and chelerythrine chlo-
ride, suppressed RA-induced JNK phosphorylation (Fig. 3B,
top panel). In addition, these inhibitors prevented induction
of NF-L (Fig. 3B, bottom panel) and neurite outgrowth in
response to RA treatment (Fig. 3C). Neither of these PKC
inhibitors had cytotoxic e¡ects at the concentrations em-
ployed in the experiments (data not shown). These results
suggested that both OA-sensitive protein phosphatase(s) and
PKC participate in the activation of JNK in the course of
RA-induced P19 cell neural di¡erentiation.
4. Discussion
In this study, we demonstrated that JNK is activated, with
little change in the JNK protein levels, during the course of
the RA-induced neural di¡erentiation of P19 cells. In addi-
tion, experiments using the ectopic expression of the wtJNK
or dnJNK in P19 cells indicated for the ¢rst time that the
activation of JNK is required for neural di¡erentiation (Fig.
2). In this context, the participation of JNK in endodermal
di¡erentiation of P19 cells using a distinct di¡erentiation-in-
ducing system had been reported by Jho et al. [4]. Signaling
systems related to neural di¡erentiation have been well docu-
mented in NGF-induced neural di¡erentiation of PC12 cells, a
rat pheochromocytoma cell line [14^17]. Studies have revealed
that the activation of JNK and p38 kinase occurs in the di¡er-
entiation of PC12 cells [15^17]. In this context, Okamoto et al.
have recently reported that phosphorylation of p38 kinase
was enhanced during induction of neural di¡erentiation by
RA [18]. Their results also indicated that the activation of
p38 kinase plays an anti-apoptotic role during neural dif-
ferentiation. These results suggest that both JNK and p38
play important roles in RA-induced P19 cell neural di¡eren-
tiation.
In addition, the G-proteins GK12 and GK13 have been
implicated in the activation of JNK through a Ras-dependent
signal transduction pathway [19]. The expression of GK12 and
GK13 also was enhanced and essential to stimulation of en-
dodermal and neuroectodermal di¡erentiation of P19 cells by
RA [20]. Therefore, GK12 and GK13 may participate in the
JNK activation which takes place concomitant with the neural
di¡erentiation of P19 cells. However, the molecular mecha-
nisms of the GK12/GK13 activation and the connection be-
tween GK12/GK13 and JNK in the course of the P19 cell
di¡erentiation have not been clari¢ed. In this study, the two
distinct PKC inhibitors of protein phosphatase (OA and tau-
Fig. 4. Schematic model of regulation of RA-induced neural di¡er-
entiation of P19 cells. PPase, protein phosphatase.
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tomycin) and the two distinct inhibitors (calphostin C and
chelerythrine chloride) suppressed the neurite outgrowth and
the NF-L expression as well as the RA-induced enhanced
phosphorylation of JNK. Therefore, we suggest that both
OA-sensitive protein phosphatase(s) and PKC participate in
the di¡erentiation-induced activation of JNK. The short-term
incubation of neurally di¡erentiated cells with OA or PKC
inhibitors did not a¡ect the JNK phosphorylation level
(data not shown). Therefore, it is likely that both OA-sensitive
protein phosphatase(s) and PKC stimulate JNK phosphory-
lation through an indirect mechanism, possibly by regulating
the expression levels or activities of proteins which are in-
volved in the activation mechanism of GK12 and GK13 or
in the signaling pathway between GK12/GK13 and JNK
(Fig. 4).
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